Compare BFST & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BFST | EVO |
|---|---|---|
| Founded | 2006 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 877.1M | 934.1M |
| IPO Year | 2014 | N/A |
| Metric | BFST | EVO |
|---|---|---|
| Price | $27.98 | $3.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $32.75 | $7.00 |
| AVG Volume (30 Days) | ★ 141.8K | 85.0K |
| Earning Date | 04-27-2026 | 04-08-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | ★ 23.45 | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $10,704,000.00 | N/A |
| Revenue This Year | $22.71 | $1.37 |
| Revenue Next Year | $5.02 | $10.05 |
| P/E Ratio | $41.16 | ★ N/A |
| Revenue Growth | ★ 1.20 | N/A |
| 52 Week Low | $22.56 | $2.31 |
| 52 Week High | $30.32 | $4.48 |
| Indicator | BFST | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 55.01 | 53.04 |
| Support Level | $26.73 | $2.88 |
| Resistance Level | $28.74 | $3.36 |
| Average True Range (ATR) | 0.53 | 0.09 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 75.72 | 54.34 |
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates the majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.